These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37385888)

  • 1. Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.
    Turley CB; Tables L; Fuller T; Sanders LJ; Scott H; Moodley A; Woodward Davis A; Leav B; Miller J; Schoemaker K; Vandebosch A; Sadoff J; Woo W; Cho I; Dunkle LM; Li S; van der Laan L; Gilbert PB; Follmann D; Jaynes H; Kublin JG; Baden LR; Goepfert P; Kotloff K; Gay CL; Falsey AR; El Sahly HM; Sobieszczyk ME; Huang Y; Neuzil KM; Corey L; Grinsztejn B; Gray G; Rouphael N; Luedtke A;
    Vaccine; 2023 Jul; 41(33):4899-4906. PubMed ID: 37385888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of COVID-19 vaccines.
    Graña C; Ghosn L; Evrenoglou T; Jarde A; Minozzi S; Bergman H; Buckley BS; Probyn K; Villanueva G; Henschke N; Bonnet H; Assi R; Menon S; Marti M; Devane D; Mallon P; Lelievre JD; Askie LM; Kredo T; Ferrand G; Davidson M; Riveros C; Tovey D; Meerpohl JJ; Grasselli G; Rada G; Hróbjartsson A; Ravaud P; Chaimani A; Boutron I
    Cochrane Database Syst Rev; 2022 Dec; 12(12):CD015477. PubMed ID: 36473651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions.
    Francis AI; Ghany S; Gilkes T; Umakanthan S
    Postgrad Med J; 2022 May; 98(1159):389-394. PubMed ID: 37066438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
    Munro APS; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Gokani K; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kwok J; Lambe T; Libri V; Llewelyn MJ; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Murira J; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Salkeld J; Saralaya D; Sharma S; Sheridan R; Sturdy A; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
    Lancet; 2021 Dec; 398(10318):2258-2276. PubMed ID: 34863358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tracking the COVID-19 vaccines: The global landscape.
    Yadav T; Kumar S; Mishra G; Saxena SK
    Hum Vaccin Immunother; 2023 Dec; 19(1):2191577. PubMed ID: 36995773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
    Sadoff J; Gray G; Vandebosch A; Cárdenas V; Shukarev G; Grinsztejn B; Goepfert PA; Truyers C; Fennema H; Spiessens B; Offergeld K; Scheper G; Taylor KL; Robb ML; Treanor J; Barouch DH; Stoddard J; Ryser MF; Marovich MA; Neuzil KM; Corey L; Cauwenberghs N; Tanner T; Hardt K; Ruiz-Guiñazú J; Le Gars M; Schuitemaker H; Van Hoof J; Struyf F; Douoguih M;
    N Engl J Med; 2021 Jun; 384(23):2187-2201. PubMed ID: 33882225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
    Cerqueira-Silva T; Andrews JR; Boaventura VS; Ranzani OT; de Araújo Oliveira V; Paixão ES; Júnior JB; Machado TM; Hitchings MDT; Dorion M; Lind ML; Penna GO; Cummings DAT; Dean NE; Werneck GL; Pearce N; Barreto ML; Ko AI; Croda J; Barral-Netto M
    Lancet Infect Dis; 2022 Jun; 22(6):791-801. PubMed ID: 35366959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Hardt K; Vandebosch A; Sadoff J; Le Gars M; Truyers C; Lowson D; Van Dromme I; Vingerhoets J; Kamphuis T; Scheper G; Ruiz-Guiñazú J; Faust SN; Spinner CD; Schuitemaker H; Van Hoof J; Douoguih M; Struyf F;
    Lancet Infect Dis; 2022 Dec; 22(12):1703-1715. PubMed ID: 36113538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
    Voysey M; Costa Clemens SA; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Clutterbuck EA; Collins AM; Cutland CL; Darton TC; Dheda K; Dold C; Duncan CJA; Emary KRW; Ewer KJ; Flaxman A; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hill C; Hill HC; Hirsch I; Izu A; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Libri V; Lillie PJ; Marchevsky NG; Marshall RP; Mendes AVA; Milan EP; Minassian AM; McGregor A; Mujadidi YF; Nana A; Padayachee SD; Phillips DJ; Pittella A; Plested E; Pollock KM; Ramasamy MN; Ritchie AJ; Robinson H; Schwarzbold AV; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; White T; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
    Lancet; 2021 Mar; 397(10277):881-891. PubMed ID: 33617777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant.
    Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L
    Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies.
    Di Fusco M; Lin J; Vaghela S; Lingohr-Smith M; Nguyen JL; Scassellati Sforzolini T; Judy J; Cane A; Moran MM
    Expert Rev Vaccines; 2022 Apr; 21(4):435-451. PubMed ID: 35112973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
    Dunkle LM; Kotloff KL; Gay CL; Áñez G; Adelglass JM; Barrat Hernández AQ; Harper WL; Duncanson DM; McArthur MA; Florescu DF; McClelland RS; Garcia-Fragoso V; Riesenberg RA; Musante DB; Fried DL; Safirstein BE; McKenzie M; Jeanfreau RJ; Kingsley JK; Henderson JA; Lane DC; Ruíz-Palacios GM; Corey L; Neuzil KM; Coombs RW; Greninger AL; Hutter J; Ake JA; Smith K; Woo W; Cho I; Glenn GM; Dubovsky F;
    N Engl J Med; 2022 Feb; 386(6):531-543. PubMed ID: 34910859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
    Shaw RH; Greenland M; Stuart ASV; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Libri V; Lillie PJ; Morey E; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; White R; Nguyen-Van-Tam JS; Liu X; Snape MD;
    J Infect; 2023 Jun; 86(6):574-583. PubMed ID: 37028454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials.
    Janes H; Fisher LH; Kee JJ; Parameswaran L; Goepfert PA; Falsey AR; Ludwig J; Magaret CA; Gilbert PB; Kublin JG; Rouphael N; Sobieszczyk ME; El Sahly HM; Baden LR; Grinsztejn B; Walsh SR; Gray GE; Kotloff KL; Gay CL; Greninger AL; Tapia MD; Hammershaimb EA; Priddy FH; Green JA; Struyf F; Dunkle L; Neuzil KM; Corey L; Huang Y
    J Infect Dis; 2024 Sep; ():. PubMed ID: 39225478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial.
    Toback S; Galiza E; Cosgrove C; Galloway J; Goodman AL; Swift PA; Rajaram S; Graves-Jones A; Edelman J; Burns F; Minassian AM; Cho I; Kumar L; Plested JS; Rivers EJ; Robertson A; Dubovsky F; Glenn G; Heath PT;
    Lancet Respir Med; 2022 Feb; 10(2):167-179. PubMed ID: 34800364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Overview of COVID-19 vaccines licensed in the EU-from technology via clinical trial to registration].
    Hildt E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Dec; 65(12):1237-1243. PubMed ID: 36257986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
    Stuart ASV; Shaw RH; Liu X; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; England A; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Horsington BM; Lambe T; Lazarus R; Libri V; Lillie PJ; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; White R; Nguyen-Van-Tam JS; Snape MD;
    Lancet; 2022 Jan; 399(10319):36-49. PubMed ID: 34883053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials.
    Sherman AC; Tuan J; Cantos VD; Adeyiga O; Mahoney S; Ortega-Villa AM; Tillman A; Whitaker J; Woodward Davis AS; Leav B; Hirsch I; Sadoff J; Dunkle LM; Gilbert PB; Janes HE; Kublin JG; Goepfert PA; Kotloff K; Rouphael N; Falsey AR; El Sahly HM; Sobieszczyk ME; Huang Y; Neuzil KM; Corey L; Grinsztejn B; Gray G; Nason M; Baden LR; Gay CL
    Clin Infect Dis; 2024 Aug; 79(2):364-374. PubMed ID: 38598658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of COVID-19 Vaccines in SARS-CoV-2 Variants.
    Zhou Z; Zhu Y; Chu M
    Front Immunol; 2022; 13():898192. PubMed ID: 35669787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022.
    Wu N; Joyal-Desmarais K; Ribeiro PAB; Vieira AM; Stojanovic J; Sanuade C; Yip D; Bacon SL
    Lancet Respir Med; 2023 May; 11(5):439-452. PubMed ID: 36780914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.